Skip to main content

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “These appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,” said Galbraith. “Adam’s deep oncology...

Continue reading

GEN Korean BBQ To Sell All Products at 190 Grocery Stores

GEN Korean BBQ Expands KBBQ Meat & Restaurant Experience with Launch of New Retail Products Inspired by Fan-Favorite Flavors CERRITOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) — GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of GEN Korean BBQ, a leading all-you-can-eat Korean BBQ chain, today announced the expansion of its retail product lineup. Following the global rise of Korean culture—from K-dramas on streaming platforms like Netflix to K-pop artists such as BTS, beauty products, and more—GEN Korean BBQ is well positioned for continued growth through its restaurant to retail product ecosystem. GEN Korean BBQ is responding to strong customer demand by introducing a selection of its most requested products for purchase, giving loyal fans the opportunity to enjoy their favorites beyond the restaurant...

Continue reading

Whitestone REIT to Be Acquired by Ares for $1.7 Billion

HOUSTON and NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) and Ares Management Corporation (NYSE: ARES) today announced that Whitestone has entered into a definitive merger agreement (the “Merger Agreement”) with certain Ares Real Estate funds (“Ares”) pursuant to which Ares will acquire all outstanding Whitestone common shares and operating partnership units for $19.00 per share or unit in an all-cash transaction valued at approximately $1.7 billion. The purchase price represents a 12.2% premium to Whitestone’s closing stock price on April 8, 2026, the last full trading day prior to the transaction announcement, and a 26.5% premium to the unaffected share price prior to the March 5, 2026 Reuters article announcing the Company had engaged advisors to explore a sale. Whitestone’s...

Continue reading

Merger Implementation Timetable

QUEBEC CITY, April 09, 2026 (GLOBE NEWSWIRE) — Predictive Discovery Limited (ASX: PDI) (“PDI”) and Robex Resources Inc. (ASX: RXR, TSX-V: RBX) (“Robex”) are pleased to advise the detailed implementation timetable for the merger between the companies (the “Transaction”). The Transaction is being implemented by way of a statutory plan of arrangement in the Province of Québec, Canada under the Business Corporations Act (Québec) (“Arrangement”), pursuant to the arrangement agreement dated 5 October 2025 (as amended). As announced on 8 April 2026, all conditions precedent have been satisfied or waived (as applicable), and the Transaction is unconditional and proceeding to completion and implementation (“Implementation”), with the effective date scheduled to occur on 15 April 2026 (“Effective Date”). Pursuant to the Implementation of...

Continue reading

Brunswick Corporation Schedules 2026 First Quarter Earnings Conference Call

METTAWA, Ill., April 09, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2026 first quarter financial results on Thursday, April 30, 2026, before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website. The results will also be available on the SEC’s website with the Form 8-K filing of the release. The Company will hold a conference call at 10 a.m. CT / 11 a.m. ET, Thursday, April 30, 2026, hosted by David M. Foulkes, chairman and chief executive officer, Ryan M. Gwillim, executive vice president, chief financial officer, and chief strategy officer, and Stephen Weiland, senior vice president, finance and deputy CFO. A copy of the presentation to be used on this call will be available when the results are released...

Continue reading

Fortuna reports production of 72,872 gold equivalent ounces in the first quarter of 2026 and provides a business update

VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) reports production results for the first quarter of 2026 from its three operating mines in West Africa and Latin America. All figures presented in this news release are expressed in U.S. dollars, unless otherwise indicated. Q1 2026 highlights ProductionProduction totaled 72,872 gold equivalent ounces (“GEO”)1, compared to 70,386 GEO in Q1 20252,3,4 and 65,130 GEO in Q4 20252,5,6Growth InitiativesSéguéla processing plant expansion studies are advancing according to plan and are expected to be completed in May 2026. The studies are evaluating an expansion scenario of approximately 28%, targeting between 2.0 to 2.5 million tonnes per year. Following successful infill drilling of the Sunbird deposit at the Séguéla Mine,...

Continue reading

Correction: The decision of the management company of INVL Technology on the purchase of own shares

Correction of the investment realization date. The Management company INVL Asset Management, UAB of INVL Technology (hereinafter – “the Company”), taking into account that the Company has formed and not realised the reserve for the purchase of own shares which is equal to EUR 9.8 million and considering the resolution of the General Shareholders Meeting of the Company held on 30 April 2025, initiates the purchase of the Company‘s own ordinary registered EUR 0.29 nominal value shares. Purchase conditions:Share purchase starts on  13 April 2026.Share purchase ends on  17 April 2026.Maximum number of shares to be acquired (units): 120,000 units.Total maximum purchase price (EUR): EUR 537,600.Maximum purchase price (EUR): EUR 4.48 per share.Share purchase price (EUR): the price shall be determined according to Dutch auction principles, i.e....

Continue reading

Virtune AB (Publ) (“Virtune”) has completed the monthly rebalancing for March 2026 of its Virtune Crypto Top 10 Index ETP – the first crypto index ETP in the Nordics

Stockholm, 9 April 2026 – Virtune today announces the completion of the monthly rebalancing for the Virtune Crypto Top 10 Index ETP, listed on Nasdaq Stockholm for both the SEK-denominated (ISIN code SE0020052207, ticker name VIR10SEK) and the EUR-denominated (ISIN code SE0020052215, ticker name VIR10EUR) ETP. In addition to the Virtune Crypto Top 10 Index ETP, Virtune’s product portfolio includes: Virtune Bitcoin ETPVirtune Stellar ETPVirtune Staked Ethereum ETPVirtune Staked Solana ETPVirtune Staked Polkadot ETPVirtune XRP ETPVirtune Avalanche ETPVirtune Litecoin ETPVirtune Chainlink ETPVirtune Arbitrum ETPVirtune Staked Polygon ETPVirtune Staked Cardano ETPVirtune Crypto Altcoin Index ETPVirtune Bitcoin Prime ETPVirtune Coinbase 50 Index ETPVirtune Staked Near ETPVirtune Sui ETPVirtune Stablecoin ETPVirtune Bittensor ETPVirtune...

Continue reading

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has successfully completed the safety run-in stage of a Phase II clinical trial in the first-line treatment of advanced biliary tract cancer (BTC). Based on favorable safety and encouraging preliminary efficacy data, the study has progressed into the expansion phase, with the first patient already enrolled. The study is led by Dr. Jian Zhou from Zhongshan Hospital, Fudan University, and is being conducted across multiple clinical sites in China. A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy...

Continue reading

Correction: Cash Flows

To Nasdaq Copenhagen A/S                        1 April 2026                                        Announcement no. 30/2026                                        Inside information Correction: The following ISINs, which have been or will be fully redeemed at the next payment date (1 July 2026), have been removed from the file: DK0009382624, DK0009369282 and DK0007802003 Cash Flows Pursuant to S. 24 of the Capital Markets Act, we hereby publish cash flow data on bonds issued by Jyske Realkredit. Please find the data in the attached file. The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com. For further information about format of data and content of the file we refer to the web site of Nasdaq at www.nasdaqomxnordic.com. Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.